

Chinese startups provide strong support for innovative ADC drug R&D

17 July 2023 | News

While GeneQuantum has developed multiple clinically advanced innovative ADC products, InxMed has made significant breakthroughs in the field of tumour resistance and metastasis



China-based biotech startups GeneQuantum and InxMed have signed a collaboration agreement. GeneQuantum has granted non-exclusive licensing of its proprietary conjugation technology to InxMed, supporting the development of the next generation of targeted conjugate ADC (antibody-drug conjugate) drugs.

According to the agreement, GeneQuantum will provide InxMed with its independently developed, globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform. This will support InxMed in developing innovative ADC drugs.

The agreement was signed following the successful concept validation results of the candidate drugs developed by both parties.

InxMed will be responsible for the research, development (R&D), manufacturing, and commercialisation of the ADC candidate molecules.

This collaboration will enable both parties to leverage their respective technological advantages and resources, accelerate the research and development process of innovative ADC drugs, and provide more treatment options for patients worldwide.